185 related articles for article (PubMed ID: 28971643)
1. Novel Therapeutic Strategies in Primary Sjögren's Syndrome.
Alunno A; Carubbi F; Bistoni O; Bartoloni E; Valentini V; Gerli R
Isr Med Assoc J; 2017 Sep; 19(9):576-580. PubMed ID: 28971643
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
3. Primary Sjogren's syndrome: current and prospective therapies.
Thanou-Stavraki A; James JA
Semin Arthritis Rheum; 2008 Apr; 37(5):273-92. PubMed ID: 17714766
[TBL] [Abstract][Full Text] [Related]
4. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
5. [Sjögren's Syndrome: Early diagnosis and effective treatment].
Witte T
Dtsch Med Wochenschr; 2018 Dec; 143(24):1778-1782. PubMed ID: 30508859
[TBL] [Abstract][Full Text] [Related]
6. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
7. Emerging biological therapies in primary Sjogren's syndrome.
Ramos-Casals M; Brito-Zerón P
Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
[TBL] [Abstract][Full Text] [Related]
8. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
[TBL] [Abstract][Full Text] [Related]
9. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.
Hansen A; Lipsky PE; Dörner T
Curr Opin Rheumatol; 2005 Sep; 17(5):558-65. PubMed ID: 16093833
[TBL] [Abstract][Full Text] [Related]
10. Biologic treatment in Sjögren's syndrome.
Sada PR; Isenberg D; Ciurtin C
Rheumatology (Oxford); 2015 Feb; 54(2):219-30. PubMed ID: 25342375
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential for B-cell modulation in Sjögren's syndrome.
Mariette X
Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420
[TBL] [Abstract][Full Text] [Related]
12. Biologic treatments in Sjögren's syndrome.
Bowman S; Barone F
Presse Med; 2012 Sep; 41(9 Pt 2):e495-509. PubMed ID: 22836195
[TBL] [Abstract][Full Text] [Related]
13. Advances in the understanding and treatment of systemic complications in Sjögren's syndrome.
Brito-Zerón P; Ramos-Casals M;
Curr Opin Rheumatol; 2014 Sep; 26(5):520-7. PubMed ID: 25050925
[TBL] [Abstract][Full Text] [Related]
14. New biological therapies in Sjögren's syndrome.
Nocturne G; Cornec D; Seror R; Mariette X
Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):783-93. PubMed ID: 27107513
[TBL] [Abstract][Full Text] [Related]
15. The management of Sjögren's syndrome.
Mavragani CP; Moutsopoulos NM; Moutsopoulos HM
Nat Clin Pract Rheumatol; 2006 May; 2(5):252-61. PubMed ID: 16932698
[TBL] [Abstract][Full Text] [Related]
16. Present and novel biologic drugs in primary Sjögren's syndrome.
Fasano S; Isenberg DA
Clin Exp Rheumatol; 2019; 37 Suppl 118(3):167-174. PubMed ID: 31025931
[TBL] [Abstract][Full Text] [Related]
17. [Primary Sjögren's syndrome--more than a dry mouth and dry eyes].
Magnus JH; Omdal R; Hinderaker W; Husby G
Nord Med; 1990; 105(10):262-3. PubMed ID: 2235472
[TBL] [Abstract][Full Text] [Related]
18. Current and potential treatments for primary Sjögren's syndrome.
Mariette X
Joint Bone Spine; 2002 Jun; 69(4):363-6. PubMed ID: 12184431
[TBL] [Abstract][Full Text] [Related]
19. Sjögren's syndrome: where do we stand, and where shall we go?
Cornec D; Jamin C; Pers JO
J Autoimmun; 2014 Jun; 51():109-14. PubMed ID: 24612946
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel CD4+ T Cell Subsets in the Target Tissue of Sjögren's Syndrome and Their Differential Regulation by the Lymphotoxin/LIGHT Signaling Axis.
Haskett S; Ding J; Zhang W; Thai A; Cullen P; Xu S; Petersen B; Kuznetsov G; Jandreski L; Hamann S; Reynolds TL; Allaire N; Zheng TS; Mingueneau M
J Immunol; 2016 Nov; 197(10):3806-3819. PubMed ID: 27815440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
